Kelkar Amar H, Antin Joseph H, Shapiro Roman M
Division of Stem Cell Transplantation and Cellular Therapies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Department of Medicine, Harvard Medical School, Boston, MA, United States.
Front Oncol. 2023 Apr 12;13:1175794. doi: 10.3389/fonc.2023.1175794. eCollection 2023.
Fifty years of hematopoietic cell transplantation (HCT) has ushered in an exciting era of cellular therapy and has led to enormous progress in improving the outcomes of patients with both malignant and non-malignant hematologic disease. As the survival of transplanted patients has increased, so has the recognition of long-term complications related to this therapy.
The goal of this review is to highlight some of the most common long-term complications of HCT.
To this end, we have conducted a review of the published literature on the long-term complications of HCT encompassing the past 50 years.
We have endeavored to include long-term complications reported in research articles, case series and case reports, reviews, and abstracts. We have focused primarily on adult allogeneic HCT, but have included some data from studies of pediatric allogeneic HCT as well. We have also prioritized the literature published in the last 15 years.
Key data supporting the onset and prevalence of the most common long-term complications was extracted.
While the list of long-term complications extracted and reported was comprehensive, it was not exhaustive.
We have endeavored to highlight some of the most common long-term complications of HCT, the recognition and management of which constitutes an important part of HCT survivorship care.
造血细胞移植(HCT)五十年来开创了一个激动人心的细胞治疗时代,并在改善恶性和非恶性血液系统疾病患者的治疗结果方面取得了巨大进展。随着移植患者生存率的提高,对这种治疗相关长期并发症的认识也在增加。
本综述的目的是强调造血细胞移植一些最常见的长期并发症。
为此,我们对过去50年中已发表的关于造血细胞移植长期并发症的文献进行了综述。
我们努力纳入研究文章、病例系列和病例报告、综述及摘要中报道的长期并发症。我们主要关注成人异基因造血细胞移植,但也纳入了一些来自儿童异基因造血细胞移植研究的数据。我们还优先考虑了过去15年发表的文献。
提取了支持最常见长期并发症的发生和患病率的关键数据。
虽然提取和报告的长期并发症列表很全面,但并非详尽无遗。
我们努力强调造血细胞移植一些最常见的长期并发症,对其的认识和管理是造血细胞移植幸存者护理的重要组成部分。